[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-daily-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-daily-headache":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100462839","phase-3-multi-center-rct-of-iv-ketamine-efficacy-and-safety-in-chronic-daily-headaches-100462839",false,"NCT05306899","Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches","A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study","KetHead","Inclusion Criteria:\n\n1. Age 18-75 years\n2. CDH diagnosis preceding trial enrollment with headache episodes lasting for 4 or more hours occurring on 15 or more days in a month for 3 or more months (International Headache Society-IHS criteria)\n3. Normal liver and kidney function tests\n\nExclusion criteria:\n\n1. Pregnant or breastfeeding patients\n2. Pre-existing renal impairment\n3. Pre-existing liver impairment\n4. Chronic benzodiazepine or antipsychotic medication use\n5. History of cerebrovascular event\n6. Significant and untreated hypertension or severe cardiac condition\n7. Hypothyroidism\n8. Glaucoma\n9. Concomitant use of strong CYP2B6 or CYP2C8 inhibitor\n10. Allergy or intolerance to ketamine\n11. Pheochromocytoma\n12. Any significant cognitive or language barriers that impede participation\n13. CGRP antagonist use in 1 month or Onabotulinum-toxin A 3 months before infusion\n14. Active diagnosis of Post-Traumatic Stress Disorder (PTSD)\n15. Active diagnosis of Substance Use Disorder\n16. Patients taking opioid medications with daily Oral Morphine Equivalents ≥80 mg","ALL","18 Years","75 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Chronic daily headaches (CDH) poses a significant burden on patients, healthcare systems and the society. Intravenous (IV) ketamine infusion, an intervention that is widely available and scalable, can treat CDH by reversing receptor-mediated sensitization. This study is a multicenter, placebo-controlled, parallel group randomized trial with blinding of participants and observers with the goal of comprehensively assessing the effect of high-dose IV ketamine infusion (1 mg.kg-1.h-1 for six hours) on the frequency and intensity of headaches, mood, activity, sleep, quality of life and safety of ketamine for three months after the interventions. Use of validated questionnaires, wearable technology, a research team that includes investigators with expertise in studying ketamine and in evaluating treatments for CDH and pain syndromes are some of the unique features of this project.\n\nOur study aims to prospectively assess the efficacy and safety of high-dose intravenous ketamine infusions compared to saline infusions in participants with CDH syndrome.",[28],"Chronic Daily Headache",[30,31,32,33],"ketamine","migraine","daily headache","chronic pain","RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2022-06-01",{"date":42,"type":22},"2027-06-01",{"name":44,"class":45},"University Health Network, Toronto","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100303521","analysis-of-headache-chronification-with-imaging-deep-phenotyping-and-proteomics-100303521","NCT03231241","Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics","SunStar Project to Explore the Chronification Process in Headache Through Functional Imaging, Deep Phenotyping, and Analysis of CSF of Blood Products","Inclusion Criteria:\n\n* Subjects must agree to sign informed consent.\n* Subject must be able to or at least with some help willing to complete online questionnaires in English .\n* Willing to comply with study instructions.\n* must speak and understand English\n\nExclusion Criteria:\n\n\\*Any neurological condition, at the discretion of the Principal Investigator (PI)",true,{"count":55,"type":22},700,"OBSERVATIONAL","Study is aimed at determining why some patients with episodic headache proceed to chronic daily or near daily headaches. The Investigators seek to discover differences in brain anatomy and function, composition of cerebrospinal fluid, blood products, genetics, and patient phenotypes that might help explain this process.",[28,59],"Chronic Migraine",[61,62,63,64],"Headaches","Tension-Type Headache","New Daily Persistent Headache (NDPH)","Migraine","2025-07-18",{"date":67,"type":38},"2025-07-23",{"date":69,"type":38},"2014-12-12",{"date":71,"type":22},"2026-09-01",{"name":73,"class":45},"Stanford University",1]